Global inactivation of carboxylesterase 1 (Ces1/Ces1g) protects against atherosclerosis in Ldlr−/− mice

被引:0
|
作者
Jiesi Xu
Yang Xu
Yanyong Xu
Liya Yin
Yanqiao Zhang
机构
[1] Northeast Ohio Medical University,Department of Integrative Medical Sciences
[2] Institute of Genetics and Developmental Biology,State Key Laboratory of Molecular Developmental Biology
[3] Chinese Academy of Sciences,undefined
来源
Scientific Reports | / 7卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Atherosclerotic cardiovascular disease is a leading cause of death in the western world. Increased plasma triglyceride and cholesterol levels are major risk factors for this disease. Carboxylesterase 1 (Ces1/Ces1g) has been shown to play a role in metabolic control. So far, the role of mouse Ces1/Ces1g deficiency in atherosclerosis is not elucidated. We generated Ces1/Ces1g−/− mice. Compared to wild-type mice, Ces1/Ces1g−/− mice had reduced plasma cholesterol levels. We then generated Ces1g−/−Ldlr−/− double knockout (DKO) mice, which were fed a Western diet for 16 weeks. Compared to Ldlr−/− mice, DKO mice displayed decreased plasma cholesterol and TG levels and reduced atherosclerotic lesions. Interestingly, knockdown of hepatic Ces1/Ces1g in Apoe−/− mice resulted in hyperlipidemia and exacerbated Western diet-induced atherogenesis. Mechanistically, global inactivation of Ces1/Ces1g inhibited intestinal cholesterol and fat absorption and Niemann-Pick C1 like 1 expression, and increased macrophage cholesterol efflux by inducing ATP-binding cassette subfamily A member 1 (ABCA1) and ABCG1. Ces1/Ces1g ablation also promoted M2 macrophage polarization and induced hepatic cholesterol 7α-hydroxylase and sterol 12α-hydroxylase expression. In conclusion, global loss of Ces1/Ces1g protects against the development of atherosclerosis by inhibiting intestinal cholesterol and triglyceride absorption and promoting macrophage cholesterol efflux.
引用
收藏
相关论文
共 50 条
  • [41] Efficient in vitro refolding and functional characterization of recombinant human liver carboxylesterase (CES1) expressed in E-coli
    Boonyuen, Usa
    Promnares, Kamoltip
    Junkree, Suwapat
    Day, Nichloas P. J.
    Imwong, Mallika
    PROTEIN EXPRESSION AND PURIFICATION, 2015, 107 : 68 - 75
  • [42] CES1 Deficiency Is Associated With Endothelial Dysfunction and Metabolic Reprograming in PAH
    Agarwal, S.
    Heo, L.
    Chakraborty, A.
    West, J. D.
    Suresh, K.
    Nair, R. V.
    Nicolls, M. R.
    Morisseau, C.
    Hammock, B. D.
    Lafyatis, R. A.
    Kawut, S. M.
    Zamanian, R. T.
    Perez, V. De Jesus
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [43] The Influence of the CES1 Genotype on the Pharmacokinetics of Enalapril in Patients with Arterial Hypertension
    Ikonnikova, Anna
    Rodina, Tatiana
    Dmitriev, Artem
    Melnikov, Evgeniy
    Kazakov, Ruslan
    Nasedkina, Tatiana
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (04):
  • [44] The Pharmacokinetics of Enalapril in Relation to CES1 Genotype in Healthy Danish Volunteers
    Stage, Claus
    Jurgens, Gesche
    Guski, Louise Schow
    Thomsen, Ragnar
    Bjerre, Ditte
    Ferrero-Miliani, Laura
    Lyauk, Yassine Kamal
    Rasmussen, Henrik Berg
    Dalhoff, Kim
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2017, 121 (06) : 487 - 492
  • [45] Individualization of treatments with drugs metabolized by CES1: combining genetics and metabolomics
    Rasmussen, Henrik Berg
    Bjerre, Ditte
    Linnet, Kristian
    Juergens, Gesche
    Dalhoff, Kim
    Stefansson, Hreinn
    Hankemeier, Thomas
    Kaddurah-Daouk, Rima
    Taboureau, Olivier
    Brunak, Soren
    Houmann, Tine
    Jeppesen, Pia
    Pagsberg, Anne Katrine
    Plessen, Kerstin
    Dyrborg, Jorgen
    Hansen, Peter Riis
    Hansen, Poul Erik
    Hughes, Tim
    Werge, Thomas
    PHARMACOGENOMICS, 2015, 16 (06) : 649 - 665
  • [46] The Impact of ABCB1 and CES1 Polymorphisms on Dabigatran Pharmacokinetics in Healthy Chinese Subjects
    Liu, Yue
    Yang, Chenguang
    Qi, Wenyuan
    Pei, Zuowei
    Xue, Wei
    Zhu, Huolan
    Dong, Min
    Guo, Ying
    Cong, Duanduan
    Wang, Fang
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2021, 14 : 477 - 485
  • [47] The impact of CES1 genotypes on the pharmacokinetics of methylphenidate in healthy Danish subjects
    Stage, Claus
    Jurgens, Gesche
    Guski, Louise Schow
    Thomsen, Ragnar
    Bjerre, Ditte
    Ferrero-Miliani, Laura
    Lyauk, Yassine Kamal
    Rasmussen, Henrik Berg
    Dalhoff, Kim
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 83 (07) : 1506 - 1514
  • [48] Rivaroxaban Showed Strong Inhibition on the Activity of Human Carboxylesterase (CES) 1
    Zhang, Ying
    Lv, Zhongying
    Sun, Lihua
    Luo, Mei
    LATIN AMERICAN JOURNAL OF PHARMACY, 2018, 37 (08): : 1526 - 1528
  • [49] DNA methylation and its involvement in carboxylesterase 1A1 (CES1A1) gene expression
    Hori, T.
    Hosokawa, M.
    XENOBIOTICA, 2010, 40 (02) : 119 - 128
  • [50] Genetic variants of ABCB1 and CES1 genes on dabigatran metabolism in the Kazakh population
    Abdrakhmanov, Ayan
    Zholdybayeva, Elena
    Shaimerdinova, Aizhana
    Kulmambetova, Gulmira
    Abildinova, Svetlana
    Albayev, Rustam
    Tuyakova, Gulnara
    Rib, Elena
    Suleimen, Zhanasyl
    Abdrakhmanova, Zhanar
    Bekbossynova, Makhabbat
    CASPIAN JOURNAL OF INTERNAL MEDICINE, 2024, 15 (03) : 499 - 508